Institutional

Max Fehlmann appointed President and Scientific Director of the IRCM

Dec. 20 2018 | Appointment

All news

Pierre Duplessis, Chair of the Montreal Clinical Research Institute (IRCM) Board of Directors, is pleased to announce the appointment of Max Fehlmann as President and Scientific Director of the Institute, effective March 1, 2019.

“Following a rigorous recruitment process, members of the Selection Committee were unanimous in recognizing Dr. Fehlmann's professional expertise in the field of basic and clinical research as well as his extensive experience as a key senior manager. The entire IRCM community joins me in welcoming him,” said Dr. Duplessis.

“It is a great honour for me to join this Quebec flagship. I accept this mandate with the vision of maintaining the excellence of this institution, which is renowned worldwide for the quality of its research and clinical work, plus its outstanding academic training,” added Dr. Fehlmann.

Dr. Fehlmann is currently the President and CEO of the Cancer Research Society. Previously, he was also Founding President and Chief Executive Officer of the NEOMED Institute as well as founding President and CEO of CQDM, a pre-competitive research consortium based in Montreal, where he helped align innovations from universities and SMEs with the needs of the industry. Dr. Fehlmann began his career in the field of research as a Visiting Scientist at Harvard Medical School in the United States, Professor of Biochemistry and Pharmacology at the Université de Nice, in France, and Research Director at the Institut national de la santé et de la recherche médicale, in Nice, France. He is the principal author of more than 100 scientific publications and 200 scientific abstracts. In the pharmaceutical sector, Dr. Fehlmann is the founder of Aster Biotechnologies in France, where he was the President and CEO, as well as the President and CEO of Chronogen in Montreal. He has also served as Zambon Group's Vice President of Research and Development in Italy for its international preclinical, clinical and business development activities. In addition, he founded Z-Cube, a venture capital and investment fund associated with the Zambon Group. Dr. Fehlmann holds a PhD in Biochemistry from Université Laval, a PhD in Pharmacology from the Université de Nice and an MBA from the Sophia-Antipolis Business Development Centre at the Université de Nice. He is currently a member of many boards of directors in Canada and France.

Dr. Fehlmann succeeds Tarik Möröy, who has held this position since 2006. Dr. Möröy will stay at the IRCM as Director of the Hematopoiesis and Cancer Research Unit.

Dr. Duplessis would like to “sincerely thank Dr. Möröy for his commitment to the Institute. His invaluable contribution over the past 13 years has ensured that the IRCM remains an international benchmark, something of which we are all very proud. His many initiatives have helped the Institute continue as one of the best in the world.”

 

Source